Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated? Mark ClemonsKent RussellChristina L. Addison Review 05 May 2012 Pages: 453 - 457
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review Caitlin C. MurphyL. Kay BartholomewSally W. Vernon Review 12 June 2012 Pages: 459 - 478
Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies D. AuneD. S. M. ChanT. Norat Review 16 June 2012 Pages: 479 - 493
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells Bisrat G. DebebEvan N. CohenWendy A. Woodward Preclinical Study 01 May 2012 Pages: 495 - 510
Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option Ziyan Yuan PessettoYing YanAmarnath Natarajan Preclinical Study 06 May 2012 Pages: 511 - 517
Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer Alaa T. AlshareedaEmad A. RakhaAndrew R. Green Preclinical Study 06 May 2012 Pages: 519 - 529
SGK3 is associated with estrogen receptor expression in breast cancer Jun XuMa WanDan Liu Preclinical Study 11 May 2012 Pages: 531 - 541
Analysis of KLLN as a high-penetrance breast cancer predisposition gene Ella R. ThompsonKylie L. GorringeIan G. Campbell Preclinical Study 13 May 2012 Pages: 543 - 547
Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients Jun TangRong DengXiao-Feng Zhu Preclinical Study 15 May 2012 Pages: 549 - 560
Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer Tobias J. GrobUwe HeilenkötterAnnette Lebeau Preclinical study 19 May 2012 Pages: 561 - 567
Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter V. BartellaP. RizzaS. Andò Preclinical study 24 May 2012 Pages: 569 - 581
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies Albert C. ChenIlenia MigliaccioRachel Schiff Preclinical Study 29 May 2012 Pages: 583 - 593
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors Carmine FedeleGennaro RiccioClaudia De Lorenzo Preclinical Study 07 June 2012 Pages: 595 - 602
Therapeutic potential for phenytoin: targeting Nav1.5 sodium channels to reduce migration and invasion in metastatic breast cancer Ming YangDavid J. KozminskiWilliam J. Brackenbury Preclinical Study Open access 08 June 2012 Pages: 603 - 615
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program Michael BilousAdrienne L. MoreyGelareh Farshid Preclinical study Open access 08 June 2012 Pages: 617 - 624
Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland Ezequiel CalvoVan Luu-TheFernand Labrie Preclinical Study 08 June 2012 Pages: 625 - 647
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells Hsiao-Ching ChuangNaval KapuriyaCharles L. Shapiro Preclinical study 08 June 2012 Pages: 649 - 659
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique M. TakadaM. SugimotoM. Toi Preclinical Study 12 June 2012 Pages: 661 - 670
AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies Cynthie WongXin WangShiuan Chen Preclinical Study 16 June 2012 Pages: 671 - 681
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study Lawrence J. SolinRobert GrayJoseph A. Sparano Clinical Trial 01 May 2012 Pages: 683 - 692
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide Jennifer GjerdeSara GandiniErnst A. Lien Clinical trial Open access 05 May 2012 Pages: 693 - 700
Expression of activated type I receptor tyrosine kinases in early breast cancer Melanie SpearsHans Christian PedersonJohn M. S. Bartlett Clinical Trial 05 May 2012 Pages: 701 - 708
Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy William JacotStéphane PouderouxPierre-Jean Lamy Clinical Trial 06 May 2012 Pages: 709 - 717
Early breast cancer with positive margins: excellent local control with an upfront brachytherapy boost Thomas M. SchroederBen LiemMelanie Royce Clinical Trial 16 May 2012 Pages: 719 - 725
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer Ivana SestakMichelle HarvieJack Cuzick Clinical Trial 16 May 2012 Pages: 727 - 734
Sentinel lymph node biopsy of the internal mammary chain in breast cancer E. L. PostmaS. van WieringenA. J. Witkamp Clinical trial Open access 08 June 2012 Pages: 735 - 741
HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases Han ZhangGuoping RenWang Bo Clinical trial 08 June 2012 Pages: 743 - 749
TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer Joseph A. SparanoLori J. GoldsteinRobert Gray Clinical trial 16 June 2012 Pages: 751 - 757
Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer David W. CesconPatricia A. GanzPamela J. Goodwin Clinical Trial 16 June 2012 Pages: 759 - 767
Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis Saroj NiraulaAlberto OcanaPamela J. Goodwin Epidemiology 05 May 2012 Pages: 769 - 781
Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease Xuefen SuGraham A. ColditzRulla M. Tamimi Epidemiology 24 May 2012 Pages: 783 - 791
Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer Maria E. C. SandbergMikael HartmanKamila Czene Epidemiology 24 May 2012 Pages: 793 - 800
Examination of ancestral informative markers and self-reported race with tumor characteristics of breast cancer among black and white women Kerryn W. RedingChristopher S. CarlsonKathleen E. Malone Epidemiology 31 May 2012 Pages: 801 - 809
Serum cotinine and prognosis in breast cancer L. JohnsonO. AgbajeI. S. Fentiman Epidemiology 08 June 2012 Pages: 811 - 814
The economic burden of metastatic breast cancer: a U.S. managed care perspective Alberto J. MonteroSara EapenPaulette Adler Epidemiology 09 June 2012 Pages: 815 - 822
Adult weight gain, fat distribution and mammographic density in Spanish pre- and post-menopausal women (DDM-Spain) Marina PollánVirginia LopeDDM-Spain Epidemiology Open access 12 June 2012 Pages: 823 - 838
Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study Sharareh TaghipourDragan BanjevicAndrew K. S. Jardine Epidemiology 12 June 2012 Pages: 839 - 851
Long-term survival of older breast cancer patients: population-based estimates over three decades Bindu KanapuruWilliam B. ErshlerJerome W. Yates Epidemiology 19 June 2012 Pages: 853 - 857
The influence of mammographic density on breast tumor characteristics Louise ErikssonKamila CzenePer Hall Epidemiology 19 June 2012 Pages: 859 - 866
The influence of non-clinical patient factors on medical oncologists’ decisions to recommend breast cancer adjuvant chemotherapy T. May PiniSarah T. HawleyJennifer J. Griggs Epidemiology 21 June 2012 Pages: 867 - 874
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010 Erika A. WatersTimothy S. McNeelAndrew N. Freedman Brief Report 24 May 2012 Pages: 875 - 880
NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup Michael RetskyRick RogersKatharina Pachmann Brief Report 24 May 2012 Pages: 881 - 888
Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry Jing ZhangJames D. FackenthalOlufunmilayo I. Olopade Brief Report 28 June 2012 Pages: 889 - 894
High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered? Miriam J. SmithFranchesca L. GiffordD. Gareth R. Evans Letter to the Editor 03 July 2012 Pages: 895 - 897
A bias in genotyping the miR-27a rs895819 and rs11671784 variants Rongxi YangBarbara Burwinkel Letter to the Editor 03 July 2012 Pages: 899 - 901
